Ken Griffin Exagen Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Exagen Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 1,600 shares of XGN stock, worth $2,912. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,600
Previous 100
1500.0%
Holding current value
$2,912
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding XGN
# of Institutions
35Shares Held
6.21MCall Options Held
1.6KPut Options Held
4.1K-
Rtw Investments, LP New York, NY1.5MShares$2.74 Million0.04% of portfolio
-
Cowen And Company, LLC899KShares$1.64 Million0.05% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT787KShares$1.43 Million0.01% of portfolio
-
Silvercrest Asset Management Group LLC New York, NY545KShares$991,6760.01% of portfolio
-
Perkins Capital Management Inc494KShares$898,2990.68% of portfolio
About EXAGEN INC.
- Ticker XGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 16,260,400
- Market Cap $29.6M
- Description
- Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...